Melphalan Aspen

Melphalan, the active ingredient in Melphalan Aspen, is an alkylating agent presented as an intravenous formulation for oncology use. It is employed in the treatment of certain blood and solid tumours, particularly in patients with multiple myeloma, ovarian cancer or malignant melanoma.

GNH USA supplies Melphalan Aspen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Melphalan is an alkylating antineoplastic used in several malignancies: - Multiple Myeloma: helps achieve disease control and prolong survival. - Ovarian Cancer: used as part of combination regimens to reduce tumour burden. - Malignant Melanoma: administered when other therapies are insufficient, aiming to slow progression.

Adverse reactions may occur with melphalan therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during infusion. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Fatigue: general tiredness during treatment cycles. - Alopecia: temporary hair loss.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related cancers. - Severe infection: due to profound neutropenia. - Pulmonary fibrosis: rare lung scarring. - Renal toxicity: impaired kidney function. - Cardiotoxicity: occasional heart rhythm disturbances.

Melphalan requires careful monitoring and patient education. - Dose adjustment: modify for renal or hepatic impairment. - Infection risk: monitor blood counts and treat infections promptly. - Pregnancy: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Breastfeeding: discontinue during therapy and for a defined period after. - Drug handling: use protective equipment to avoid accidental exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan may interact with several concomitant medicines.

Major Interactions (Avoid): - Live vaccines: increased risk of infection due to immunosuppression. - High‑dose cyclophosphamide: additive myelosuppression. - Nephrotoxic agents (e.g., cisplatin): heightened renal toxicity.

Moderate Interactions (Monitor Closely): - Antifungal azoles: may increase melphalan plasma levels. - Allopurinol: can potentiate bone‑marrow suppression. - NSAIDs: may exacerbate renal impairment when combined.